Volume 29, Number 2—February 2023
Research
Age-Stratified Model to Assess Health Outcomes of COVID-19 Vaccination Strategies, Ghana
Table 1
Parameter values for age-stratified SEPIARD-V COVID-19 model to assess health outcomes of COVID-19 vaccination strategies, Ghana*
Parameter | Symbol | Value | References |
---|---|---|---|
Mean latency period which is the period from exposure to infectiousness |
1/k |
1.85 d |
Abbasi et al. (18), Liu et al. (19) |
Mean duration of being infectious and symptomatic |
1/f |
15.7 d |
Cai et al. (20), Xing et al. (21) |
Mean duration of being infectious and asymptomatic |
1/q |
7.25 d |
Ma et al. (22), Byrne et al. (23) |
Mean duration of being infectious and presymptomatic |
1/c |
2.9 d |
Tindale et al. (24), Byrne et al. (23) |
Reproduction number for the initial strain |
R |
3.13 |
Armachie et al., unpub. data, https://doi.org/10.20944/preprints202104.0125.v1 |
Reproduction number for the Delta strain |
R |
5.35 |
Pearson et al., unpub. data, https://doi.org/10.1101/2021.12.19.21268038 |
Probability of exposed person becoming presymptomatically infected |
δ |
0.30 |
Chen et al. (25), Buitrago-Garcia et al. (26) |
Vaccine efficacy against infection |
σ |
0.745 |
Knoll et al. (27) |
Relative transmissibility of asymptomatic persons |
u |
0.75 |
CDC (28) |
Relative transmissibility of presymptomatic persons |
r |
0.75 |
CDC (28) |
Mean duration of immunity after vaccination |
χ |
182 d |
Iacobucci (29) |
Mean duration of immunity after natural infection |
w |
365 d |
Good and Hawkes (30) |
Age-specific case-fatality ratio |
z |
0.002 for <25 y, 0.005 for 25–64 y, 0.048 for ≥65 y |
Our World in Data (January 26, 2021–November 12, 2021; 22), Lawal (31) |
Daily vaccination rate | v | Varied by 0.00009–0.0163977 d–1 per person | Estimated |
*CDC, Centers for Disease Control and Prevention; SEPIARD-V, Susceptible-Exposed-Presymptomatic-Symptomatic-Asymptomatic-Recovered-Dead-Vaccinated.
References
- Ghana Health Service. COVID-19 Ghana's outbreak response management updates. 2022 [cited 2023 Jan 06]. https://ghanahealthservice.org/covid19/archive.php
- Ofori SK, Schwind JS, Sullivan KL, Cowling BJ, Chowell G, Fung IC-H. Transmission dynamics of COVID-19 in Ghana and the impact of public health interventions. Am J Trop Med Hyg. 2022;107:175–9. DOIPubMedGoogle Scholar
- Quakyi NK, Agyemang Asante NA, Nartey YA, Bediako Y, Sam-Agudu NA. Ghana’s COVID-19 response: the Black Star can do even better. BMJ Glob Health. 2021;6:
e005569 . DOIPubMedGoogle Scholar - Alhassan RK, Aberese-Ako M, Doegah PT, Immurana M, Dalaba MA, Manyeh AK, et al. COVID-19 vaccine hesitancy among the adult population in Ghana: evidence from a pre-vaccination rollout survey. Trop Med Health. 2021;49:96. DOIPubMedGoogle Scholar
- World Health Organization Africa. More COVID-19 vaccines arrive in Ghana. 2021. [cited 2022 Dec 6]. https://www.afro.who.int/news/more-covid-19-vaccines-arrive-ghana
- Ghana Health Service. COVID-19 Ghana’s outbreak response management updates. 2020 [cited 2022 Feb 21]. https://ghanahealthservice.org/covid19/archive.php
- Botwe BO, Antwi WK, Adusei JA, Mayeden RN, Akudjedu TN, Sule SD. COVID-19 vaccine hesitancy concerns: Findings from a Ghana clinical radiography workforce survey. Radiography (Lond). 2022;28:537–44. DOIPubMedGoogle Scholar
- Quashie PK, Mutungi JK, Dzabeng F, Oduro-Mensah D, Opurum PC, Tapela K, et al. Trends of SARS-CoV-2 antibody prevalence in selected regions across Ghana. Wellcome Open Res. 2021;6:173. DOIGoogle Scholar
- Alagoz O, Sethi AK, Patterson BW, Churpek M, Alhanaee G, Scaria E, et al. The impact of vaccination to control COVID-19 burden in the United States: A simulation modeling approach. PLoS One. 2021;16:
e0254456 . DOIPubMedGoogle Scholar - Moghadas SM, Vilches TN, Zhang K, Wells CR, Shoukat A, Singer BH, et al. The impact of vaccination on coronavirus disease 2019 (COVID-19) outbreaks in the United States. Clin Infect Dis. 2021;73:2257–64. DOIPubMedGoogle Scholar
- Matrajt L, Eaton J, Leung T, Brown ER. Vaccine optimization for COVID-19: Who to vaccinate first? Sci Adv. 2021;7:
eabf1374 . DOIPubMedGoogle Scholar - Mumtaz GR, El-Jardali F, Jabbour M, Harb A, Abu-Raddad LJ, Makhoul M. Modeling the impact of COVID-19 vaccination in Lebanon: a call to speed-up vaccine roll out. Vaccines (Basel). 2021;9:697. DOIPubMedGoogle Scholar
- Bubar KM, Reinholt K, Kissler SM, Lipsitch M, Cobey S, Grad YH, et al. Model-informed COVID-19 vaccine prioritization strategies by age and serostatus. Science. 2021;371:916–21. DOIPubMedGoogle Scholar
- University of British Columbia Department of Zoology. COVID-19 models lecture. 2020 [cited 2020 Nov 15]. https://www.zoology.ubc.ca/~bio301/Bio301/Lectures/Lecture1/COVID_Models.pdf
- Wei WE, Li Z, Chiew CJ, Yong SE, Toh MP, Lee VJ. Presymptomatic Transmission of SARS-CoV-2 - Singapore, January 23-March 16, 2020. MMWR Morb Mortal Wkly Rep. 2020;69:411–5. DOIPubMedGoogle Scholar
- Li Y, Shi J, Xia J, Duan J, Chen L, Yu X, et al. Asymptomatic and symptomatic patients with non-severe coronavirus disease (COVID-19) have similar clinical features and virological courses: a retrospective single center study. Front Microbiol. 2020;11:1570. DOIPubMedGoogle Scholar
- Zhao H, Lu X, Deng Y, Tang Y, Lu J. COVID-19: asymptomatic carrier transmission is an underestimated problem. Epidemiol Infect. 2020;148:e116-e.
- Abbasi Z, Zamani I, Mehra AHA, Shafieirad M, Ibeas A. Optimal control design of impulsive SQEIAR epidemic models with application to COVID-19. Chaos Solitons Fractals. 2020;139:
110054 . DOIPubMedGoogle Scholar - Liu Z, Magal P, Seydi O, Webb G. A COVID-19 epidemic model with latency period. Infect Dis Model. 2020;5:323–37. DOIPubMedGoogle Scholar
- Cai Q, Huang D, Ou P, Yu H, Zhu Z, Xia Z, et al. COVID-19 in a designated infectious diseases hospital outside Hubei Province, China. Allergy. 2020;75:1742–52. DOIPubMedGoogle Scholar
- Xing YH, Ni W, Wu Q, Li WJ, Li GJ, Wang WD, et al. Prolonged viral shedding in feces of pediatric patients with coronavirus disease 2019. J Microbiol Immunol Infect. 2020;53:473–80. DOIPubMedGoogle Scholar
- Ma S, Zhang J, Zeng M, Yun Q, Guo W, Zheng Y, et al. Epidemiological parameters of COVID-19: cases series study. J Med Internet Res. 2020;22:
e19994 . DOIPubMedGoogle Scholar - Byrne AW, McEvoy D, Collins AB, Hunt K, Casey M, Barber A, et al. Inferred duration of infectious period of SARS-CoV-2: rapid scoping review and analysis of available evidence for asymptomatic and symptomatic COVID-19 cases. BMJ Open. 2020;10:
e039856 . DOIPubMedGoogle Scholar - Tindale LC, Stockdale JE, Coombe M, Garlock ES, Lau WYV, Saraswat M, et al. Evidence for transmission of COVID-19 prior to symptom onset. eLife. 2020;9:
e57149 . DOIPubMedGoogle Scholar - Chen M, Li M, Hao Y, Liu Z, Hu L, Wang L. The introduction of population migration to SEIAR for COVID-19 epidemic modeling with an efficient intervention strategy. Inf Fusion. 2020;64:252–8. DOIPubMedGoogle Scholar
- Buitrago-Garcia D, Egli-Gany D, Counotte MJ, Hossmann S, Imeri H, Ipekci AM, et al. Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: a living systematic review and meta-analysis. PLoS Med. 2020;17:e1003346-e.
- Knoll MD, Wonodi C. Oxford-AstraZeneca COVID-19 vaccine efficacy. Lancet. 2021;397:72–4. DOIPubMedGoogle Scholar
- Centers for Disease Control and Prevention. Pandemic planning scenarios. 2020 [cited 2020 Nov 12]. https://www.cdc.gov/coronavirus/2019-ncov/hcp/planning-scenarios.html
- Iacobucci G. Covid-19: Protection from two doses of vaccine wanes within six months, data suggest. BMJ. 2021;374:n2113. DOIPubMedGoogle Scholar
- Good MF, Hawkes MT. The interaction of natural and vaccine-induced immunity with social distancing predicts the evolution of the COVID-19 Pandemic. MBio. 2020;11:e02617–20. DOIPubMedGoogle Scholar
- Lawal Y. Africa’s low COVID-19 mortality rate: A paradox? Int J Infect Dis. 2021;102:118–22. DOIPubMedGoogle Scholar
- Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al. Effectiveness of Covid-19 vaccines against the B. 1.617. 2 (Delta) variant. N Engl J Med. 2021;385:585–94. DOIPubMedGoogle Scholar
- le Polain de Waroux O, Cohuet S, Ndazima D, Kucharski AJ, Juan-Giner A, Flasche S, et al. Characteristics of human encounters and social mixing patterns relevant to infectious diseases spread by close contact: a survey in Southwest Uganda. BMC Infect Dis. 2018;18:172. DOIPubMedGoogle Scholar
- Kiti MC, Kinyanjui TM, Koech DC, Munywoki PK, Medley GF, Nokes DJ. Quantifying age-related rates of social contact using diaries in a rural coastal population of Kenya. PLoS One. 2014;9:
e104786 . DOIPubMedGoogle Scholar - Trentini F, Guzzetta G, Galli M, Zardini A, Manenti F, Putoto G, et al. Modeling the interplay between demography, social contact patterns, and SARS-CoV-2 transmission in the South West Shewa Zone of Oromia Region, Ethiopia. BMC Med. 2021;19:89. DOIPubMedGoogle Scholar
- Central Intelligence Agency. The world factbook. 2020 [cited 2022 Jan 15]. https://www.cia.gov/the-world-factbook
- Anaadem P. Ghana: population hits 30.8 million—Greater Accra most populous region—GSS. Ghana Today. 2021 Sep 22 [cited 2022 Dec 6]. https://ghanatoday.gov.gh/news/ghanas-population-hits-30-8-million-greater-accra-most-populous-region-gss/
- Foy BH, Wahl B, Mehta K, Shet A, Menon GI, Britto C. Comparing COVID-19 vaccine allocation strategies in India: A mathematical modelling study. Int J Infect Dis. 2021;103:431–8. DOIPubMedGoogle Scholar
- Ko Y, Lee J, Kim Y, Kwon D, Jung E. COVID-19 vaccine priority strategy using a heterogenous transmission model based on maximum likelihood estimation in the Republic of Korea. Int J Environ Res Public Health. 2021;18:6469. DOIPubMedGoogle Scholar
- Diarra M, Kebir A, Talla C, Barry A, Faye J, Louati D, et al.; REPAIR consortium. Non-pharmaceutical interventions and COVID-19 vaccination strategies in Senegal: a modelling study. BMJ Glob Health. 2022;7:
e007236 . DOIPubMedGoogle Scholar - Buckner JH, Chowell G, Springborn MR. Dynamic prioritization of COVID-19 vaccines when social distancing is limited for essential workers. Proc Natl Acad Sci U S A. 2021;118:
e2025786118 . DOIPubMedGoogle Scholar - Chapman LAC, Shukla P, Rodríguez-Barraquer I, Shete PB, León TM, Bibbins-Domingo K, et al. Risk factor targeting for vaccine prioritization during the COVID-19 pandemic. Sci Rep. 2022;12:3055. DOIPubMedGoogle Scholar
- Acheampong T, Akorsikumah EA, Osae-Kwapong J, Khalid M, Appiah A, Amuasi JH. Examining vaccine hesitancy in sub-saharan Africa: a survey of the knowledge and attitudes among adults to receive COVID-19 vaccines in Ghana. Vaccines (Basel). 2021;9:814. DOIPubMedGoogle Scholar
- Nikolovski J, Koldijk M, Weverling GJ, Spertus J, Turakhia M, Saxon L, et al. Factors indicating intention to vaccinate with a COVID-19 vaccine among older U.S. adults. PloS one. 2021;16:e0251963-e.
- Dembek ZF, Schwartz-Watjen KT, Swiatecka AL, Broadway KM, Hadeed SJ, Mothershead JL, et al. Coronavirus disease 2019 on the heels of Ebola virus disease in West Africa. Pathogens. 2021;10:1266. DOIPubMedGoogle Scholar
- Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, et al. Covid-19 vaccine effectiveness against the Omicron (B.1.1.529) variant. N Engl J Med. 2022;386:1532–46. DOIPubMedGoogle Scholar